5-fluorouracil potentiates the anti-cancer effect of oxaliplatin on Colo320 colorectal adenocarcinoma cells

Journal of Gastrointestinal and Liver Diseases

Volumn 22, Issue 1, 2013, Pages 37-43

  Berindan Neagoe, Ioana ^a,b,c   Braicu, Cornelia ^a,c   Pileczki, Valentina ^b,c   Petric, Roxana Cojocneanu ^c,d   Miron, Nicolae ^b,e   Balacescu, Ovidiu ^a   Iancu, Dana ^f   Ciuleanu, Tudor ^f  

^a Oncological Institute Ion Chiricuta   (Romania)

^b IULIU HATIEGANU UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

^c IULIU HATIEGANU UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

^d BABE BOLYAI UNIVERSITY   (Romania)

^e Clinical Laboratory IRGH'Prof dr O Fodor'   (Romania)

^f Oncological Institute Ion Chiricuta Cluj   (Romania)

Author keywords

5 fluorouracil; Apoptosis; Colo320; Colorectal cancer; Oxaliplatin

Indexed keywords

DEATH RECEPTOR; FLUOROURACIL; OXALIPLATIN; ANTINEOPLASTIC AGENT; PLATINUM COMPLEX;

APOPTOSIS; ARTICLE; CELL PROLIFERATION; COLORECTAL CARCINOMA; CONTROLLED STUDY; DOWN REGULATION; DRUG RESPONSE; FLOW CYTOMETRY; GENE EXPRESSION; GENE REGULATORY NETWORK; HUMAN; HUMAN CELL; IC 50; NECROSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; TREATMENT RESPONSE; UPREGULATION; ADENOCARCINOMA; COLORECTAL NEOPLASMS; DOSE RESPONSE; DRUG EFFECTS; DRUG POTENTIATION; DRUG SCREENING; GENE EXPRESSION REGULATION; GENETICS; PATHOLOGY; PROCEDURES; REAL TIME POLYMERASE CHAIN REACTION; TUMOR CELL CULTURE;

ADENOCARCINOMA; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; CELL PROLIFERATION; COLORECTAL NEOPLASMS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SCREENING ASSAYS, ANTITUMOR; DRUG SYNERGISM; FLUOROURACIL; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; ORGANOPLATINUM COMPOUNDS; REAL-TIME POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; TUMOR CELLS, CULTURED;

EID: 84875460992     PISSN: 18418724     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (41)

1. Alberts SR, Wagman LD. Chemotherapy for colorectal cancer liver metastases. Oncologist 2008; 13:1063-1073.
2. Board RE, Valle JW. Metastatic colorectal cancer: current systemic treatment options. Drugs 2007; 67: 1851-1867.
3. Wang X, Li M, Wanga J, et al. The BH3-only protein, PUMA, is involved in oxaliplatin-induced apoptosis in colon cancer cells. Biochem Pharmacol 2006; 71:1540-1550.
4. Hato SV, de Vries IJ, Lesterhuis WJ. STATing the importance of immune modulation by platinum chemotherapeutics. Oncoimmunology 2012; 1: 234-236.
5. Kadoyama K, Miki I, Tamura T, Brown JB, Sakaeda T, Okuno Y. Adverse event profiles of 5-fluorouracil and capecitabine: data mining of the public version of the FDA Adverse Event Reporting System, AERS, and reproducibility of clinical observations. Int J Med Sci 2012; 9: 33-39.
6. Caraglia M, Marra M, Budillon A, et al. Chemotherapy regimen GOLF induces apoptosis in colon cancer cells through multi-chaperone complex inactivation and increased Raf-1 ubiquitin-dependent degradation. Cancer Biol Ther 2005; 4: 1159-1167.
7. Raymond E, Faivre S, Coudray AM, Louvet C, Gespach C. Preclinical studies of oxaliplatin in combination chemotherapy. Bull Cancer 2001; 88: S26-34.
8. Mani S, Manalo J, Bregman D. Novel combinations with oxaliplatin. Oncology 2000; 14: 52-8.
9. Qiao L, Wong B. Colon Cancer Experimental Therapy. In: Schwab M. (Ed.) Encyclopedia of Cancer: Springer Reference (www. springerreference.com). Springer-Verlag Berlin Heidelberg, 2009.
10. Chibaudel B, Tournigand C, André T, de Gramont A. Therapeutic strategy in unresectable metastatic colorectal cancer. Ther Adv Med Oncol 2012; 4: 75-89.
11. Reed JC Apoptosis-targeted therapies for cancer. Cancer Cell 2003; 3: 17-22.
12. Stevenson L, Allen WL, Turkington R, et al. Identification of galanin and its receptor GalR1 as novel determinants of resistance to chemotherapy and potential biomarkers in colorectal cancer. Clin Cancer Res 2012; 18:5412-5426.
13. Margiotta N, Marzano C, Gandin V, et al. Revisiting [PtCl(2)(cis-1,4-DACH)]: an underestimated antitumor drug with potential application to the treatment of oxaliplatin-refractory colorectal cancer. J Med Chem 2012; 55: 7182-7192.
14. Mori R, Yoshida K, Tanahashi T, et al. Decreased FANCJ caused by 5FU contributes to the increased sensitivity to oxaliplatin in gastric cancer cells. Gastric Cancer 2012 Sep 12. [Epub ahead of print].
15. Amm HM, Oliver PG, Lee CH, Li Y, Buchsbaum DJ.Combined modality therapy with TRAIL or agonistic death receptor antibodies. Cancer Biol Ther 2011; 11: 431-449.
16. Rodriquez-Nieto S, Zhivotovsky B. Role of alterations in the apoptotic machinery in sensitivity of cancer cells to treatment. Curr Pharm Des 2006; 12: 4411-4425.
17. Gao J, Tian Y Zhang J. Overexpression of interferon regulatory factor 1 enhances chemosensitivity to 5-fluorouracil in gastric cancer cells. J Cancer Res Ther 2012; 8: 57-61.
18. Lin WL, Li DG, Chen Q, Lu HM. Clinical and experimental study of oxaliplatin in treating human gastric carcinoma. World J Gastroenterol 2004; 10: 2911-2915.
19. Harradine KA, Kassner M, Chow D, et al. Functional genomics reveals diverse cellular processes that modulate tumor cell response to oxaliplatin. Mol Cancer Res 2011; 9:173-182.
20. Gherman C, Pileczki V, Cojocneanu Petric R, Rapuntean S2, Gherman S, Berindan Neagoe I. Molecular mechanisms of action and prediction of response to oxaliplatin in colorectal cancer cells. Annals of RSCB 2012; 17: 194-200.
21. Fujie Y Yamamoto H, Ngan CY, et al. Oxaliplatin, a potent inhibitor of survivin, enhances paclitaxel-induced apoptosis and mitotic catastrophe in colon cancer cells. Jpn J Clin Oncol 2005; 35: 453-463.
22. Toscano F, Fajoui ZE, Gay F, et al. P53-mediated upregulation of DcR1 impairs oxaliplatin/TRAIL-induced synergistic anti-tumour potential in colon cancer cells. Oncogene 2008; 27: 4161-4171.
23. Arnould S, Hennebelle I, Canal P, Bugat R, Guichard S. Cellular determinants of oxaliplatin sensitivity in colon cancer cell lines. Eur J Cancer 2003; 39:112-119.
24. Marchetti P, Galla DA, Russo FP, et al. Apoptosis induced by oxaliplatin in human colon cancer HCT15 cell line. Anticancer Res 2004; 24: 219-226.
25. Ravaioli A, Marangolo M, Pasquini E, et al. Bolus fluorouracil and leucovorin with oxaliplatin as first-line treatment in metastatic colorectal cancer. J Clin Oncol 2002; 20: 2545-2550.
26. Zhang, L, Fang B. Mechanisms of resistance to trail-induced apoptosis in cancer. Cancer Gene Ther 2005; 12: 228-237.
27. Peng H, Wen J, Li H, Chang J, Zhou X. Drug inhibition profile prediction for NFκB pathway in multiple myeloma. PLoS One 2011; 6: e14750.
28. Braicu C, Gherman C. Epigallocatechin gallate induce cell death and apoptosis in triple negative breast cancer cells Hs578T. J Drug Target 2012 Nov 19. [Epub ahead of print].
29. Chaudhry P, Srinivasan R, Patel FD. Differential expression of Fas family members and Bcl-2 family members in benign versus malignant epithelial ovarian cancer (EOC) in North Indian population. Mol Cell Biochem 2012;368:119-126.
30. Hamed EA, Zakhary MM, Maximous DW. Apoptosis, angiogenesis, inflammation, and oxidative stress: basic interactions in patients with early and metastatic breast cancer. J Cancer Res Clin Oncol 2012; 138: 999-1009.
31. Rigas A, Dervenis C, Giannakou N, Kozoni V, ShiffSJ, Rigas B. Selective induction of colon cancer cell apoptosis by 5-fluorouracil in humans. Cancer Invest 2002; 20: 657-665.
32. Uetsuka H, Haisa M, Kimura M, et al. Inhibition of inducible NF-kappaB activity reduces chemoresistance to 5-fluorouracil in human stomach cancer cell line. Exp Cell Res 2003; 289: 27-35.
33. Romanish MT, Nakamura H, Lai CB, Wang Y, Mager DL. A novel protein isoform of the multicopy human NAIP gene derives from intragenic Alu SINE promoters. PLoS ONE 2009; 4: e5761.
34. Wang Q, Wang X, Evers BM. Induction of cIAP-2 in human colon cancer cells through PKC delta/NF-kappa B. J Biol Chem 2003; 278: 51091-51099.
35. Chau I, Cunningham D. Treatment in advanced colorectal cancer: what, when and how? Br J Cancer 2009; 100: 1704-1719.
36. Stolfi C, Pallone F, Monteleone G. Molecular Targets of TRAIL-Sensitizing Agents in Colorectal Cancer. Int J Mol Sci 2012;13:7886-7901.
37. Dohi T, Burkly LC The TWEAK/Fn14 pathway as an aggravating and perpetuating factor in inflammatory diseases: focus on inflammatory bowel diseases. J Leukoc Biol 2012; 92: 265-279.
38. Jakubowski A, Browning B, Lukashev M, et al. Dual role for TWEAK in angiogenic regulation. J Cell Sci 2002; 115: 267-274.
39. Kumar M, Makonchuk DY, Li H, Mittal A, Kumar A. TNF-like weak inducer of apoptosis (TWEAK) activates proinflammatory signaling pathways and gene expression through the activation of TGF-beta activated kinase 1. J Immunol 2009; 182: 2439-2448.
40. Bhattacharjee M, Raju R, Radhakrishnan A, et al. A Bioinformatics Resource for TWEAK-Fn14 Signaling Pathway. J Signal Transduct 2012; 2012: 376470.
41. Liu J, Fu XQ, Zhou W, Yu HG, Yu JP, Luo HS. LY294002 potentiates the anti-cancer effect of oxaliplatin for gastric cancer via death receptor pathway. World J Gastroenterol 2011; 17: 181-190.